Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD issues advice on cascade use of antibiotics
antibiotics
VMD has released a position statement in response to concerns over antibiotic use on the cascade.
Vets report conflict between responsible use and legal requirements

The Veterinary Medicines Directorate (VMD) is calling for professional bodies, veterinary schools and research institutes to work together to help vets make a more informed choice when prescribing antibiotics on the cascade.

Veterinary surgeons have raised concerns with the VMD about the difficulty of balancing the responsible use of antibiotics with legal requirements to prescribe UK authorised medicines before applying the cascade.

According to the VMD, vets are reporting an increasingly common challenge - where there is an authorised medicine that is a critically important antibiotic (CIA) and/or is not narrow spectrum. Under legislative requirements, this should be used as a first line treatment, rather than an unauthorised, non-CIA drug.

However, in some cases, other products authorised for use in other EU member states may be more appropriate in terms of the responsible use of antibiotics.

In response to these concerns, the VMD has issued its position statement on prescribing antibiotics under the cascade.

On a case-by-case basis, the directorate says it is "justified" to to prescribe an antibiotic on the cascade to reduce the development of resistance.

Vets must demonstrate that they have considered the most appropriate active substance(s), formulation, posology, current patterns of resistance in their locality, awareness of how to reduce selection pressure and other factors, such as good biosecurity, husbandry, hygiene and avoidance of surgical sepsis.

VMD is calling for the industry to collaborate on compiling up-to-date evidence and guidance to help vets make an informed choice based on scientific evidence and peer reviewed data.

Vets are also advised to keep up-to-date with the latest guidance provided by organisations including the BVA, BSAVA, BEVA, Pig Veterinary Society and Responsible Use of Medicines in Agriculture.

For the full position statement, see the VMD website: http://www.vmd.defra.gov.uk/pdf/cascade.pdf

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.